Lessons from osteopetrotic mutations in animals: Impact on our current understanding of osteoclast biology

Critical Reviews in Eukaryotic Gene Expression

Volumn 15, Issue 2, 2005, Pages 133-162

  Van Wesenbeeck, Liesbeth ^a   Van Hul, Wim ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Animal models; Bone; Bone resorption; Osteoclast; Osteopetrosis

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BETA3 INTEGRIN; CATHEPSIN K; CHLORIDE CHANNEL; COLONY STIMULATING FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KILLER CELL ACTIVATING RECEPTOR ASSOCIATED PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOPROTEGERIN; PROTEIN BCL 2; PROTEIN C JUN; PROTON PUMP; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR MITF; TRANSCRIPTION FACTOR PU 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

ALBERS SCHOENBERG DISEASE; BONE DEMINERALIZATION; BONE REMODELING; BONE TURNOVER; C FMS GENE; CELL ADHESION; CELL FUSION; CELL INTERACTION; CELL POLARITY; DYSOSTOSIS; GENE MUTATION; GENETIC HETEROGENEITY; GLANZMANN DISEASE; HEMATOPOIETIC STEM CELL; HUMAN; MEMBRANOUS LIPODYSTROPHY; NONHUMAN; ONCOGENE; ONCOGENE C FOS; ONCOGENE SRC; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOSCLEROSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; PYKNODYSOSTOSIS; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; SPECIES COMPARISON; TIETZE SYNDROME; WAARDENBURG SYNDROME;

ANIMALS; BONE RESORPTION; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, MUTANT STRAINS; MICE, TRANSGENIC; MUTATION; OSTEOCLASTS; OSTEOPETROSIS; RATS;

ANIMALIA;

EID: 24644501631     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevEukaryotGeneExpr.v15.i2.40     Document Type: Review

References (218)

1. Marks SC Jr, Gartland A, Odgren PR. Skeletal development. In: Martino L, editor. Encyclopedia of endocrine diseases. Vol 4. Milan: Elsevier; 2004. p. 261-72.
2. Odgren PR, Gartland A, Mason-Savas A, Marks SC Jr. Bone structure. In: Martino L, editor. Encyclopedia of endocrine diseases. Vol 1. Milan: Elsevier, 2004. p. 392-400.
3. Lin JT, Lane JM. Osteoporosis: a review. Clin Orthop 2004; 425:126-34.
4. Janssens K, Van HuI W. Molecular genetics of too much bone. Hum Mol Genet 2002; 11(20):2385-93.
5. Marks SC Jr, Seifert MF, Fox RR. The osteopetrotic rabbit: general and skeletal features of a new outbred stock. Bone 1986; 7(5):359-64.
6. Lees GE, Sautter JH. Anemia and osteopetrosis in a dog. J Am Vet Med Assoc 1979; 175(8):820-4.
7. Gopal T, Leipold HW, Dennis SM. Hydatidiform moles in Holstein cattle. Vet Rec 1980; 107(17):395-7.
8. Smith RE, Ivanyi J. Pathogenesis of virus-induced osteopetrosis in the chicken. J Immunol 1980; 125(2):523-30.
9. Smits B, Bubenik GA. Congenital osteopetrosis in white-tailed deer (Odocoileus virginianus). J Wildl Dis 1990; 26(4):567-71.
10. Kawaguchi N, Ono T, Mochii M, Noda M. Spontaneous mutation in Mitf gene causes osteopetrosis in silver homozygote quail. Dev Dyn 2001; 220(2):133-40.
11. Fisher RC, Scott EW. Role of PU.1 in hematopoiesis. Stem Cells 1998; 16(1):25-37.
12. Scott EW, Simon MC, Anastasi J, Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 1994; 265(5178):1573-7.
13. Tondravi MM, McKercher SR, Anderson K, Erdmann JM, Quiroz M, Maki R, et al. Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature 1997; 386(6620):81-4.
14. McKercher SR, Torbett BE, Anderson KL, Henkel GW, Vestal DJ, Baribault H, et al. Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J 1996; 15(20):5647-58.
15. Anderson KL, Smith KA, Conners K, McKercher SR, Maki RA, Torbett BE. Myeloid development is selectively disrupted in PU.1 null mice. Blood 1998; 91(10):3702-10.
16. Rosenbauer F, Wagner K, Kutok JL, Iwasaki H, Le Beau MM, Okuno Y, et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet 2004; 36(6):624-30.
17. Roth P, Stanley ER. The biology of CSF-1 and its receptor. Curr Top Microbiol Immunol 1992; 181:141-67.
18. Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H, et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990; 345(6274):442-4.
19. Kawasaki ES, Ladner MB. Molecular biology of macrophage colony-stimulating factor. Immunol Ser 1990; 49:155-76.
20. Marks SC Jr. Morphological evidence of reduced bone resorption in osteopetrotic (op) mice. Am J Anat 1982; 163(2):157-67.
21. Wiktor-Jedrzejczak W, Bartocci A, Ferrante AW Jr, Ahmed-Ansari A, Sell KW, Pollard JW, et al. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci U S A 1990; 87(12):4828-32.
22. Cohen PE, Chisholm O, Arceci RJ, Stanley ER, Pollard JW. Absence of colony-stimulating factor-1 in osteopetrotic (csfmop/csfmop) mice results in male fertility defects. Biol Reprod 1996; 55(2):310-7.
23. Pollard JW, Stanley ER. Pleiotropic roles for CSF-1 in development defined by the mouse mutation osteopetrotic. Adv Dev Bioch 1996; 4:153-193.
24. Michaelson MD, Bieri PL, Mehler MF, Xu H, Arezzo JC, Pollard JW, et al. CSF-1 deficiency in mice results in abnormal brain development. Development 1996; 122(9):2661-72.
25. Marks SC Jr, Seifert MF, McGuire JL. Congenitally osteopetrotic (oplop) mice are not cured by transplants of spleen or bone marrow cells from normal littermates. Metab Bone Dis Relat Res 1984; 5(4):183-6.
26. Felix R, Cecchini MG, Fleisch H. Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse. Endocrinology 1990; 127(5):2592-4.
27. Sundquist KT, Cecchini MG, Marks SC Jr. Colony-stimulating factor-1 injections improve but do not cure skeletal sclerosis in osteopetrotic (op) mice. Bone 1995; 16(1):39-46.
28. Dai XM, Zong XH, Sylvestre V, Stanley ER. Incomplete restoration of colony-stimulating factor 1 (CSF-1) function in CSF-1-deficient Csf1op/Csf1op mice by transgenic expression of cell surface CSF-1. Blood 2004; 103(3):1114-23.
29. Begg SK, Radley JM, Pollard JW, Chisholm OT, Stanley ER, Bertoncello I. Delayed hematopoietic development in osteopetrotic (op/op) mice. J Exp Med 1993; 177(1):237-42.
30. Ida-Yonemochi H, Ishibashi O, Sakai H, Saku T. Recruitment of osteoclasts in the mandible of osteopetrotic (op/op) mice. Eur J Oral Sci 2004; 112(2):148-55.
31. Wiktor-Jedrzejczak W, Urbanowska E, Szperl M. Granulocyte-macrophage colony-stimulating factor corrects macrophage deficiencies, but not osteopetrosis, in the colony-stimulating factor-1-deficient op/ op mouse. Endocrinology 1994; 134(4):1932-5.
32. Nilsson SK, Lieschke GJ, Garcia-Wijnen CC, Williams B, Tzelepis D, Hodgson G, et al. Granulocyte-macrophage colony-stimulating factor is not responsible for the correction of hematopoietic deficiencies in the maturing op/op mouse. Blood 1995; 86(1):66-72.
33. Lieschke GJ, Stanley E, Grail D, Hodgson G, Sinickas V, Gall JA, et al. Mice lacking both macrophage- and granulocyte-macrophage colony-stimulating factor have macrophages and coexistent osteopetrosis and severe lung disease. Blood 1994; 84(1):27-35.
34. Stanley E, Lieschke GJ, Grail D, Metcalf D, Hodgson G, Gall JA, et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci U S A 1994; 91(12):5592-6.
35. Hodge JM, Kirkland MA, Nicholson GC. GM-CSF cannot substitute for M-CSF in human osteoclastogenesis. Biochem Biophys Res Commun 2004; 321(1):7-12.
36. Lean JM, Fuller K, Chambers TJ. FLT3 ligand can substitute for macrophage colony-stimulating factor in support of osteoclast differentiation and function. Blood 2001; 98(9):2707-13.
37. Myint YY, Miyakawa K, Naito M, Shultz LD, Oike Y, Yamamura K, et al. Granulocyte/macrophage colony-stimulating factor and interleukin-3 correct osteopetrosis in mice with osteopetrosis mutation. Am J Pathol 1999; 154(2):553-66.
38. Hoang T. The origin of hematopoietic cell type diversity. Oncogene 2004; 23(43):7188-98.
39. Wodnar-Filipowicz A. Flt3 ligand: role in control of hematopoietic and immune functions of the bone marrow. News Physiol Sci 2003; 18:247-51.
40. Niida S, Kaku M, Amano H, Yoshida H, Kataoka H, Nishikawa S, et al. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med 1999; 190(2):293-8.
41. Nakagawa M, Kaneda T, Arakawa T, Morita S, Sato T, Yomada T, et al. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 2000; 473(2):161-4.
42. Kodama I, Niida S, Sanada M, Yoshiko Y, Tsuda M, Maeda N, et al. Estrogen regulates the production of VEGF for osteoclast formation and activity in op/op mice. J Bone Miner Res 2004; 19(2):200-6.
43. Hume DA, Favot P. Is the osteopetrotic (op/op mutant) mouse completely deficient in expression of macrophage colony-stimulating factor? J Interferon Cytokine Res 1995; 15(4):279-84.
44. Cotton WR, Gaines JF. Unerupted dentition secondary to congenital osteopetrosis in the Osborne-Mendel rat. Proc Soc Exp Biol Med 1974; 146:554-61.
45. Seifert MF, Popoff SN, Marks SC Jr. Skeletal biology in the toothless (osteopetrotic) rat. Am J Anat 1988; 183(2):158-65.
46. Marks SC Jr, Iizuka T, MacKay CA, Mason-Savas A, Cielinski MJ. The effects of colony-stimulating factor-1 on the number and ultrastructure of osteoclasts in toothless (tl) rats and osteopetrotic (op) mice. Tissue Cell 1997; 29(5):589-95.
47. Seifert MF. Abnormalities in bone cell function and endochondral ossification in the osteopetrotic toothless rat. Bone 1996; 19(4):329-38.
48. Odgren PR, Popoff SN, Safadi FF, MacKay CA, Mason-Savas A, Seifert MF, et al. The toothless osteopetrotic rat has a normal vitamin D-binding protein-macrophage activating factor (DBP-MAF) cascade and chondrodysplasia resistant to treatments with colony stimulating factor-1 (CSF-1) and/or DBP-MAF. Bone 1999; 25(2):175-81.
49. Marks SC Jr, Lundmark C, Christersson C, Wurtz T, Odgren PR, Seifert MF, et al. Endochondral bone formation in toothless (osteopetrotic) rats: failures of chondrocyte patterning and type X collagen expression. Int J Dev Biol 2000; 44(3):309-16.
50. Aharinejad S, Marks SC Jr, Bock P, Mason-Savas A, MacKay CA, Larson EK, et al. CSF-1 treatment promotes angiogenesis in the metaphysis of osteopetrotic (toothless, tl) rats. Bone 1995; 16(3):315-24.
51. Watanabe H, MacKay CA, Kislauskis E, Mason-Savas A, Marks SC Jr. Ultrastructural evidence of abnormally short and maldistributed actin stress fibers in osteopetrotic (toothless) rat osteoblasts in situ after detergent perfusion. Tissue Cell 1997; 29(1):89-98.
52. Watanabe H, Kislauskis EH, Mackay CA, Mason-Savas A, Marks SC Jr. Actin mRNA isoforms are differentially sorted in normal osteoblasts and sorting is altered in osteoblasts from a skeletal mutation in the rat. J Cell Sci 1998; 111 (Pt 9):1287-92.
53. Symons AL, MacKay CA, Leong K, Hume DA, Waters MJ, Marks SC Jr. Decreased growth hormone receptor expression in long bones from toothless (osteopetrotic) rats and restoration by treatment with colony-stimulating factor-1. Growth Factors 1996; 13(1-2):1-10.
54. Joseph BK, Marks SC Jr, Hume DA, Waters MJ, Symons AL. Insulin-like growth factor-I (IGF-I) and IGF-I receptor (IGF-IR) immunoreactivity in normal and osteopetrotic (toothless, tl/tl) rat tibia. Growth Factors 1999; 16(4):279-91.
55. Seifert MF, Gray RW, Bruns ME. Elevated 1,25-dihydroxyvitamin D3 and intestinal calbindin-D9k in the toothless rat. Am J Physiol 1990; 258(2 Pt 1): E377-81.
56. Marks SC Jr. Osteopetrosis in the toothless (tl) rat: presence of osteoclasts but failure to respond to parathyroid extract or to be cured by infusion of spleen or bone marrow cells from normal littermates. Am J Anat 1977; 149(2):289-97.
57. Hermey DC, Popoff SN, Marks SC Jr. Reduced bone resorption in toothless (osteopetrotic) rats-an abnormality of osteoblasts related to their inability to activate osteoclast activity in vitro. Connect Tissue Res 1996; 35(1-4):273-8.
58. Marks SC Jr, Wojtowicz A, Szperl M, Urbanowska E, MacKay CA, Wiktor-Jedrzejczak W, et al. Administration of colony stimulating factor-1 corrects some macrophage, dental, and skeletal defects in an osteopetrotic mutation (toothless, tl) in the rat. Bone 1992; 13(1):89-93.
59. Kim N, Odgren PR, Kim DK, Marks SC Jr, Choi Y. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci U S A 2000; 97(20):10905-10.
60. Odgren PR, Kim N, van Wesenbeeck L, MacKay C, Mason-Savas A, Safadi FF, et al. Evidence that the rat osteopetrotic mutation toothless (tl) is not in the TNFSF11 (TRANCE, RANKL, ODF, OPGL) gene. Int J Dev Biol 2001; 45(8):853-9.
61. Van Wesenbeeck L, Odgren PR, MacKay CA, D'Angelo M, Safadi FF, Popoff SN, et al. The osteopetrotic mutation toothless (tl) is a loss-of-function frameshift mutation in the rat Csf1 gene: Evidence of a crucial role for CSF-1 in osteoclastogenesis and endochondral ossification. Proc Natl Acad Sci U S A 2002; 99(22):14303-8.
62. Dobbins DE, Sood R, Hashiramoto A, Hansen CT, Wilder RL, Remmers EF. Mutation of macrophage colony stimulating factor (Csf1) causes osteopetrosis in the tl rat. Biochem Biophys Res Commun 2002; 294(5):1114-20.
63. Dai XM, Ryan GR, Hapel AJ, Dominguez MG, Russell RG, Kapp S, et al. oTargeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 2002; 99(1):111-20.
64. Dai XM, Zong XH, Akhter MP, Stanley ER. Osteoclast deficiency results in disorganized matrix, reduced mineralization, and abnormal osteoblast behavior in developing bone. J Bone Miner Res 2004; 19(9):1441-51.
65. Wagner EF. Functions of API (Fos/Jun) in bone development. Ann Rheum Dis 2002; 61 Suppl 2: ii40-2.
66. Wagner EF, Matsuo K. Signalling in osteoclasts and the role of Fos/AP1 proteins. Ann Rheum Dis 2003; 62 Suppl 2:ii83-5.
67. Matsuo K, Ray N. Osteoclasts, mononuclear phagocytes, and c-Fos: new insight into osteoimmunology. Keio J Med 2004; 53(2):78-84.
68. Wang ZC, Ovitt C, Grigoriadis AE, Mohle-Steinlein U, Ruther U, Wagner EF. Bone and haematopoietic defects in mice lacking c-fos. Nature 1992; 360(6406):741-5.
69. Johnson RS, Spiegelman BM, Papaioannou V. Pleiotropic effects of a null mutation in the c-fos protooncogene. Cell 1992; 71(4):577-86.
70. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994; 266(5184) :443-8.
71. Matsuo K, Owens JM, Tonko M, Elliott C, Chambers TJ, Wagner EF. Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat Genet 2000; 24(2):184-7.
72. Fleischmann A, Hafezi F, Elliott C, Reme CE, Ruther U, Wagner EF. Fra-1 replaces c-Fos-dependent functions in mice. Genes Dev 2000; 14(21):2695-700.
73. Johnson RS, van Lingen B, Papaioannou VE, Spiegelman BM. A null mutation at the c-jun locus causes embryonic lethality and retarded cell growth in culture. Genes Dev 1993; 7(7B):1309-17.
74. Ikeda F, Nishimura R, Matsubara T, Tanaka S, Inoue J, Reddy SV, et al. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest 2004; 114(4):475-84.
75. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001; 142(12):5050-5.
76. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397(6717):315-23.
77. Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003; 101(6):2094-8.
78. Giuliani N, Colla S, Rizzoli V. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). Exp Hematol 2004; 32(8):685-91.
79. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 2000; 97(4):1566-71.
80. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999; 13(18):2412-24.
81. Kapur RP, Yao Z, Iida MH, Clarke CM, Doggett B, Xing L, et al. Malignant autosomal recessive osteopetrosis caused by spontaneous mutation of murine rank. J Bone Miner Res 2004; 19(10):1689-1697.
82. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89(2):309-19.
83. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12(9):1260-8.
84. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/ osteoprotegerin. Biochem Biophys Res Commun 1998; 247(3):610-5.
85. Kaifu T, Nakahara J, Inui M, Mishima K, Momiyama T, Kaji M, et al. Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. J Clin Invest 2003; 111(3):323-32.
86. Humphrey MB, Ogasawara K, Yao W, Spusta SC, Daws MR, Lane NE, et al. The signaling adapter protein DAP12 regulates multinucleation during osteoclast development. J Bone Miner Res 2004; 19(2):224-34.
87. Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 2004; 428(6984):758-63.
88. Mocsai A, Humphrey MB, Van Ziffle JA, Hu Y, Burghardt A, Spusta SC, et al. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci U S A 2004; 101(16):6158-63.
89. Lee ZH, Kim HH. Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem Biophys Res Commun 2003; 305(2):211-4.
90. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423(6937):337-42.
91. Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 1993; 75(2):229-40.
92. Lanier LL, Bakker AB. The ITAM-bearing transmembrane adaptor DAP12 in lymphoid and myeloid cell function. Immunol Today 2000; 21(12):611-4.
93. -/- osteoclast phenotype. J Cell Biochem 2003; 90(5):871-83.
94. Kim N, Takami M, Rho J, Josien R, Choi Y. A novel member of the leukocyte receptor complex regulates osteoclast differentiation. J Exp Med 2002; 195(2):201-9.
95. Ishikawa S, Arase N, Suenaga T, Saita Y, Noda M, Kuriyama T, et al. Involvement of FcRgamma in signal transduction of osteoclast-associated receptor (OSCAR). Int Immunol 2004; 16(7):1019-25.157
96. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002; 3(6):889-901.
97. Bradley JR, Pober JS. Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 2001; 20(44):6482-91.
98. Tsitsikov EN, Laouini D, Dunn IF, Sannikova TY, Davidson L, Alt FW, et al. TRAF1 is a negative regulator of TNF signaling. Enhanced TNF signaling in TRAF1-deficient mice. Immunity 2001; 15(4):647-57.
99. Shiels H, Li X, Schumacker PT, Maltepe E, Padrid PA, Sperling A, et al. TRAF4 deficiency leads to tracheal malformation with resulting alterations in air flow to the lungs. Am J Pathol 2000; 157(2):679-88.
100. Nakano H, Sakon S, Koseki H, Takemori T, Tada K, Matsumoto M, et al. Targeted disruption of Traf5 gene causes defects in CD40- and CD27-mediated lymphocyte activation. Proc Natl Acad Sci U S A 1999; 96(17):9803-8.
101. Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A, et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999; 13(8):1015-24.
102. Naito A, Azuma S, Tanaka S, Miyazaki T, Takaki S, Takatsu K, et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 1999; 4(6):353-62.
103. Armstrong AP, Tometsko ME, Glaccum M, Sutherland CL, Cosman D, Dougall WC. A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem 2002; 277(46):44347-56.
104. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14:649-83.
105. Sha WC, Liou HC, Tuomanen EI, Baltimore D. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell 1995; 80(2):321-30.
106. Franzoso G, Carlson L, Poljak L, Shores EW, Epstein S, Leonardi A, et al. Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecrure. J Exp Med 1998; 187(2):147-59.
107. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 1997; 3(11):1285-9.
108. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, et al. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 1997; 11(24):3482-96.
109. Xing L, Bushnell TP, Carlson L, Tai Z, Tondravi M, Siebenlist U, et al. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J Bone Miner Res 2002; 17(7):1200-10.
110. Moore KJ. Insight into the microphthalmia gene. Trends Genet 1995; 11(11):442-8.
111. Hodgkinson CA, Moore KJ, Nakayama A, Steingrimsson E, Copeland NG, Jenkins NA, et al. Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell 1993; 74(2):395-404.
112. Murphy HM. The osteopetrotic syndrome in the microphthalmic mutant mouse. Calcif Tissue Res 1973; 13(1):19-26.
113. Nii A, Steingrimsson E, Copeland NG, Jenkins NA, Ward JM. Mild osteopetrosis in the microphthalmia-oak ridge mouse. A model for intermediate autosomal recessive osteopetrosis in humans. Am J Pathol 1995; 147(6):1871-82.
114. Steingrimsson E, Moore KJ, Lamoreux ML, Ferre-D'Amare AR, Burley SK, Zimring DC, et al. Molecular basis of mouse microphthalmia (mi) mutations helps explain their developmental and phenotypic consequences. Nat Genet 1994; 8(3):256-63.
115. Hemesath TJ, Steingrimsson E, McGill G, Hansen MJ, Vaught J, Hodgkinson CA, et al. microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev 1994; 8(22):2770-80.
116. Walker DG. Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells. Science 1975; 190(4216):784-5.
117. Walker DG. Spleen cells transmit osteopetrosis in mice. Science 1975; 190(4216):785-7.
118. Holtrop ME, Cox KA, Eilon G, Simmons HA, Raisz LG. The ultrastructure of osteoclasts in microphthalmic mice. Metab Bone Dis Relat Res 1981; 3(2):123-9.
119. Thesingh CW, Scherft JP. Fusion disability of embryonic osteoclast precursor cells and macrophages in the microphthalmic osteopetrotic mouse. Bone 1985; 6(1):43-52.
120. Steingrimsson E, Tessarollo L, Pathak B, Hou L, Arnheiter H, Copeland NG, et al. Mitf and Tfe3, two members of the Mitf-Tfe family of bHLH-Zip transcription factors, have important but functionally redundant roles in osteoclast development. Proc Natl Acad Sci U S A 2002; 99(7):4477-82.
121. Luchin A, Purdom G, Murphy K, Clark MY, Angel N, Cassady AI, et al. The microphthalmia transcription factor regulates expression of the tartrate-resistant acid phosphatase gene during terminal differentiation of osteoclasts. J Bone Miner Res 2000; 15(3):451-60.
122. Motyckova G, Weilbaecher KN, Horstmann M, Rieman DJ, Fisher DZ, Fisher DE. Linking osteopetrosis and pycnodysostosis: regulation of cathepsin K expression by the microphthalmia transcription factor family. Proc Natl Acad Sci U S A 2001; 98(10):5798-803.
123. McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, Nishimura EK, et al. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 2002; 109(6):707-18.
124. Wojtowicz A, Moutier R, Grzesik W, Dziedzic-Goclawska A, Lamendin H, Ostrowski K. Early and transient osteopetrosis in microphthalmic MIB-rats. Arch Ital Anat Embriol 1990; 95(3-4):209-21.
125. Cielinski MJ, Marks SC Jr. Bone metabolism in the osteopetrotic rat mutation microphthalmia blanc. Bone 1995; 16(5):567-74.
126. Weilbaecher KN, Hershey CL, Takemoto CM, Horstmann MA, Hemesath TJ, Tashjian AH, et al. Age-resolving osteopetrosis: a rat model implicating microphthalmia and the related transcription factor TFE3. J Exp Med 1998; 187(5):775-85.
127. Opdecamp K, Vanvooren P, Riviere M, Arnheiter H, Motta R, Szpirer J, et al. The rat microphthalmia-associated transcription factor gene (Mitf) maps at 4q34-q41 and is mutated in the mib rats. Mamm Genome 1998; 9(8):617-21.
128. Mochii M, Ono T, Matsubara Y, Eguchi G. Spontaneous transdifferentiation of quail pigmented epithelial cell is accompanied by a mutation in the Mitf gene. Dev Biol 1998; 196(2):145-59.
129. Stenbeck G. Formation and function of the ruffled border in osteoclasts. Semin Cell Dev Biol 2002; 13(4):285-92.
130. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997; 13:513-609.
131. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991; 64(4):693-702.
132. Lowe C, Yoneda T, Boyce BF, Chen H, Mundy GR, Soriano P. Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc Natl Acad Sci U S A 1993; 90(10):4485-9.
133. Boyce BF, Yoneda T, Lowe C, Soriano P, Mundy GR. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 1992; 90(4):1622-7.
134. Amling M, Neff L, Priemel M, Schilling AF, Rueger JM, Baron R. Progressive increase in bone mass and development of odontomas in aging osteopetrotic c-src-deficient mice. Bone 2000; 27(5):603-10.
135. -/- mutant mice. Genes Dev 1997; 11(21):2835-44.
136. Xing L, Venegas AM, Chen A, Garrett-Beal L, Boyce BF, Varmus HE, et al. Genetic evidence for a role for Src family kinases in TNF family receptor signaling and cell survival. Genes Dev 2001; 15(2):241-53.
137. Miyazaki T, Sanjay A, Neff L, Tanaka S, Home WC, Baron R. Src kinase activity is essential for osteoclast function. J Biol Chem 2004; 279(17):17660-6.
138. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69(1):11-25.
139. Shattil SJ. Function and regulation of the beta 3 integrins in hemostasis and vascular biology. Thromb Haemost 1995; 74(1):149-55.
140. Duong LT, Lakkakorpi P, Nakamura I, Rodan GA. Integrins and signaling in osteoclast function. Matrix Biol 2000; 19(2):97-105.
141. Hodivala-Dilke KM, McHugh KP, Tsakiris DA, Rayburn H, Crowley D, Ullman-Cullere M, et al. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest 1999; 103(2):229-38.
142. McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, Novack D, et al. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 2000; 105(4):433-40.
143. Feng X, Novack DV, Faccio R, Ory DS, Aya K, Boyer MI, et al. A Glanzmann's mutation in beta 3 integrin specifically impairs osteoclast function. J Clin Invest 2001; 107(9):1137-44.
144. Vaananen HK, Zhao H, Mulari M, Halleen JM. The cell biology of osteoclast function. J Cell Sci 2000; 113(Pt 3):377-81.
145. Li YP, Chen W, Liang Y, Li E, Stashenko P. Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification. Nat Genet 1999; 23(4):447-51.
146. Seifert MF, Marks SC Jr. Morphological evidence of reduced bone resorption in the osteosclerotic (oc) mouse. Am J Anat 1985; 172(2):141-53.
147. Seifert MF, Marks SC Jr. Congenitally osteosclerotic (oc/oc) mice are resistant to cure by transplantation of bone marrow or spleen cells from normal littermates. Tissue Cell 1987; 19(1):29-37.
148. Van Slyke MA, Marks SC Jr. Failure of normal osteoclasts to resorb calcified cartilage from osteosclerotic (oc/oc) mice in vitro. Bone 1987; 8(1):39-44.
149. Wiktor-Jedrzejczak W, Szczylik C, Ratajczak MZ, Ahmed A. Congenital murine osteopetrosis inherited with osteosclerotic (oc) gene: hematological characterization. Exp Hematol 1986; 14(9):819-26.
150. Udagawa N, Sasald T, Akatsu T, Takahashi N, Tanaka S, Tamura T, et al. Lack of bone resorption in osteosclerotic (oc/oc) mice is due to a defect in osteoclast progenitors rather than the local microenvironment provided by osteoblastic cells. Biochem Biophys Res Commun 1992; 184(1):67-72.
151. Scimeca JC, Franchi A, Trojani C, Parrinello H, Grosgeorge J, Robert C, et al. The gene encoding the mouse homologue of the human osteoclast-specific 116-kDa V-ATPase subunit bears a deletion in osteosclerotic (oc/oc) mutants. Bone 2000; 26(3):207-13.
152. Nakamura I, Takahashi N, Udagawa N, Moriyama Y, Kurokawa T, Jimi E, et al. Lack of vacuolar proton ATPase association with the cytoskeleton in osteoclasts of osteosclerotic (oc/oc) mice. FEBS Lett 1997; 401(2-3):207-12.
153. Kornak U, Kasper D, Bosl MR, Kaiser E, Schweizer M, Schulz A, et al. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 2001; 104(2):205-15.
154. Goto T, Yamaza T, Tanaka T. Cathepsins in the osteoclast. J Electron Microsc (Tokyo) 2003; 52(6):551-8.
155. Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A 1998; 95(23):13453-8.
156. Gowen M, Lazner F, Dodds R, Kapadia R, Feild J, Tavaria M, et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 1999; 14(10):1654-63.
157. Halleen JM, Raisanen SR, Alatalo SL, Vaananen HK. Potential function for the ROS-generating activity of TRACP. J Bone Miner Res 2003; 18(10):1908-11.
158. Andersson G, Ek-Rylander B, Hollberg K, Ljusberg-Sjolander J, Lang P, Norgard M, et al. TRACP as an osteopontin phosphatase. J Bone Miner Res 2003; 18(10):1912-5.
159. Hayman AR, Jones SJ, Boyde A, Foster D, Colledge WH, Carlton MB, et al. Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disrupted endochondral ossification and mild osteopetrosis. Development 1996; 122(10):3151-62.
160. Hollberg K, Hultenby K, Hayman A, Cox T, Andersson G. Osteoclasts from mice deficient in tartrate-resistant acid phosphatase have altered ruffled borders and disturbed intracellular vesicular transport. Exp Cell Res 2002; 279(2):227-38.
161. Hayman AR, Cox TM. Tartrate-resistant acid phosphatase knockout mice. J Bone Miner Res 2003; 18(10):1905-7.
162. Vaaraniemi J, Halleen JM, Kaarlonen K, Ylipahkala H, Alatalo SL, Andersson G, et al. Intracellular machinery for matrix degradation in bone-resorbing osteoclasts. J Bone Miner Res 2004; 19(9):1432-40.
163. Cassady AI, Luchin A, Ostrowski MC, Hume DA. Regulation of the murine TRACP gene promoter. J Bone Miner Res 2003; 18(10):1901-4.
164. Saftig P, Hartmann D, Lullmann-Rauch R, Wolff J, Evers M, Koster A, et al. Mice deficient in lysosomal acid phosphatase develop lysosomal storage in the kidney and central nervous system. J Biol Chem 1997; 272(30):18628-35.
165. Suter A, Everts V, Boyde A, Jones SJ, Lullmann-Rauch R, Hartmann D, et al. Overlapping functions of lysosomal acid phosphatase (LAP) and tartrate-resistant acid phosphatase (Acp5) revealed by doubly deficient mice. Development 2001; 128(23):4899-910.
166. Rajapurohitam V, Chalhoub N, Benachenhou N, Neff L, Baron R, Vacher J. The mouse osteopetrotic grey-lethal mutation induces a defect in osteoclast maturation/function. Bone 2001; 28(5):513-23.
167. Chalhoub N, Benachenhou N, Rajapurohitam V, Pata M, Ferron M, Frattini A, et al. Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. Nat Med 2003; 9(4):399-406.
168. Fischer T, De Vries L, Meerloo T, Farquhar MG. Promotion of G alpha i3 subunit down-regulation by GIPN, a putative E3 ubiquitin ligase that interacts with RGS-GAIP. Proc Natl Acad Sci U S A 2003; 100(14):8270-5.
169. De Vries L, Elenko E, McCaffery JM, Fischer T, Hubler L, McQuistan T, et al. RGS-GAIP, a GTPase-activating protein for Galphai heterotrimeric G proteins, is located on clathrin-coated vesicles. Mol Biol Cell 1998; 9(5):1123-34.
170. Hermey DC, Ireland RA, Zerwekh JE, Popoff SN. Regulation of mineral homeostasis in osteopetrotic (op) rats. Am J Physiol 1995; 268(2 Pt 1):E312-7.
171. Marks SC Jr, Popoff SN. Osteoclast biology in the osteopetrotic (op) rat. Am J Anat 1989; 186(4):325-34.
172. Nisbet NW, Waldron SF, Marshall MJ. Failure of thymic grafts to stimulate
173. Remmers EF, Du Y, Ding YP, Kotake S, Ge L, Zha H, et al. Localization of the gene responsible for the op (osteopetrotic) defect in rats on chromosome 10. J Bone Miner Res 1996; 11(12):1856-61.
174. Dobbins DE, Joe B, Hashiramoto A, Salstrom JL, Dracheva S, Ge L, et al. Localization of the mutation responsible for osteopetrosis in the op rat to a 1.5-cM genetic interval on rat chromosome 10: identification of positional candidate genes by radiation hybrid mapping. J Bone Miner Res 2002; 17(10):1761-7.
175. Marks SC Jr. Pathogenesis of osteopetrosis in the ia rat: reduced bone resorption due to reduced osteoclast function. Am J Anat 1973; 138(2):165-89.
176. Marks SC Jr. Osteopetrosis in the IA rat cured by spleen cells from a normal littermate. Am J Anat 1976; 146(3):331-8.
177. Reinholt FP, Hultenby K, Heinegard D, Marks SC Jr, Norgard M, Anderson G. Extensive clear zone and defective ruffled border formation in osteoclasts of osteopetrotic (ia/ia) rats: implications for secretory function. Exp Cell Res 1999; 251(2):477-91.
178. Van Wesenbeeck L, Odgren PR, Mackay CA, Van Hul W. Localization of the gene causing the osteopetrotic phenotype in the incisors absent (ia) rat on chromosome 10q32.1. J Bone Miner Res 2004; 19(2):183-9.
179. Marks SC Jr, MacKay CA, Seifert MF. The osteopetrotic rabbit: skeletal cytology and ultrastructure. Am J Anat 1987; 178(3):300-7.
180. Lenhard S, Popoff SN, Marks SC Jr. Defective osteoclast differentiation and function in the osteopetrotic (os) rabbit. Am J Anat 1990; 188(4):438-44.
181. Popoff SN, Marks SC Jr. Congenitally osteosderotic (os/os) rabbits are not cured by bone marrow transplantation from normal littermates. Am J Anat 1991; 192(3):274-80.
182. Leipold HW, Cook JE. Animal model: osteopetrosis in Angus and Hereford calves. Am J Pathol 1977; 86(3):745-8.
183. Smith RE. Avian osteopetrosis. Curr Top Microbiol Immunol 1982; 101:75-94.
184. Sly WS, Hewett-Emmett D, Whyte MP, Yu YS, Tashian RE. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci U S A 1983; 80(9):2752-6.
185. Lewis SE, Erickson RP, Barnett LB, Venta PJ, Tashian RE. N-ethyl-N-nitrosourea-induced null mutation at the mouse Car-2 locus: an animal model for human carbonic anhydrase II deficiency syndrome. Proc Natl Acad Sci U S A 1988; 85(6):1962-6.
186. Tashian RE, Hewett-Emmett D, Dodgson SJ, Forster RE 2nd, Sly WS. The value of inherited deficiencies of human carbonic anhydrase isozymes in understanding their cellular roles. Ann N Y Acad Sci 1984; 429:262-75.
187. Kornak U, Schulz A, Friedrich W, Uhlhaas S, Kremens B, Voit T, et al. Mutations in the a3 subunit of the vacuolar H(+)-ATPase cause infantile malignant osteopetrosis. Hum Mol Genet 2000; 9(13):2059-63.
188. Frattini A, Orchard PJ, Sobacchi C, Giliani S, Abinun M, Mattsson JP, et al. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat Genet 2000; 25(3):343-6.
189. el Khazen N, Faverly D, Vamos E, Van Regemorter N, Flament-Durand J, Carton B, et al. Lethal osteopetrosis with multiple fractures in utero. Am J Med Genet 1986; 23(3):811-9.
190. Flanagan AM, Massey HM, Wilson C, Vellodi A, Horton MA, Steward CG. Macrophage colony-stimulating factor and receptor activator NF-kappaB ligand fail to rescue osteoclast-poor human malignant infantile osteopetrosis in vitro. Bone 2002; 30(1):85-90.
191. Horton WA, Schimke RN, Iyama T. Osteopetrosis: further heterogeneity. J Pediatr 1980; 97(4):580-5.
192. Hughes AE, Ralston SH, Marken J, Bell C, MacPherson H, Wallace RG, et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet 2000; 24(1):45-8.
193. Whyte MP, Hughes AE. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J Bone Miner Res 2002; 17(1):26-9.
194. Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, et al. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 2002; 347(3):175-84.
195. Cundy T, Hegde M, Naot D, Chong B, King A, Wallace R, et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 2002; 11(18):2119-27.
196. Paloneva J, Kestila M, Wu J, Salminen A, Bohling T, Ruotsalainen V, et al. Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat Genet 2000; 25(3):357-61.
197. Bianchin MM, Capella HM, Chaves DL, Steindel M, Grisard EC, Ganev GG, et al. Nasu-Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy-PLOSL): a dementia associated with bone cystic lesions. From clinical to genetic and molecular aspects. Cell Mol Neurobiol 2004; 24(1):1-24.
198. Smith SD, Kelley PM, Kenyon JB, Hoover D. Tietz syndrome (hypopigmentation/deafness) caused by mutation of MITF. J Med Genet 2000; 37(6):446-8.
199. Nobukuni Y, Watanabe A, Takeda K, Skarka H, Tachibana M. Analyses of loss-of-function mutations of the MITF gene suggest that haploinsufficiency is a cause of Waardenburg syndrome type 2A. Am J Hum Genet 1996; 59(1):76-83.
200. Tietz W. A syndrome of deaf-mutism associated with albinism showing dominant autosomal inheritance. Am J Hum Genet 1963; 15:259-64.
201. Read AP, Newton VE. Waardenburg syndrome. J Med Genet 1997; 34(8):656-65.
202. Brandwood CP, Hoyland JA, Hillarby MC, Berry JL, Davies M, Selby PL, et al. Apoptotic gene expression in Paget's disease: a possible role for Bcl-2. J Pathol 2003; 201(3):504-12.
203. Nair S, Ghosh K, Kulkarni B, Shetty S, Mohanty D. Glanzmann's thrombasthenia: updated. Platelets 2002; 13(7):387-93.
204. Horton MA, Massey HM, Rosenberg N, Nicholls B, Seligsohn U, Flanagan AM. Upregulation of osteoclast alpha2beta1 integrin compensates for lack of alphavbeta3 vitronectin receptor in Iraqi-Jewish-type Glanzmann thrombasthenia. Br J Haematol 2003; 122(6):950-7.
205. Yarali N, Fisgin T, Duru F, Kara A. Osteopetrosis and Glanzmann's thrombasthenia in a child. Ann Hematol 2003; 82(4):254-6.
206. Kocher MS, Kasser JR. Osteopetrosis. Am J Orthop 2003; 32(5):222-8.
207. Cleiren E, Benichou O, Van Hul E, Gram J, Bollerslev J, Singer FR, et al. Albers-Schonberg disease (autosomal dominant Osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet 2001; 10(25):2861-7.
208. Campos-Xavier AB, Saraiva JM, Ribeiro LM, Munnich A, Cormier-Daire V. Chloride channel 7 (CLCN7) gene mutations in intermediate autosomal recessive Osteopetrosis. Hum Genet 2003; 112(2):186-9.
209. Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996; 273(5279):1236-8.
210. Ramirez A, Faupel J, Goebel I, Stiller A, Beyer S, Stockle C, et al. Identification of a novel mutation in the coding region of the grey-lethal gene OSTM1 in human malignant infantile osteopetrosis. Hum Mutat 2004; 23(5):471-6.
211. Quarello P, Forni M, Barberis L, Defilippi C, Campagnoli MF, Silvestro L, et al. Severe malignant osteopetrosis caused by a GL gene mutation. J Bone Miner Res 2004; 19(7):1194-9.
212. Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Benichou O, Scopelliti D, et al. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 2003; 72(3):763-71.
213. Bollerslev J. Autosomal dominant osteopetrosis: bone metabolism and epidemiological, clinical, and hormonal aspects. Endocr Rev 1989; 10(1):45-67.
214. Bollerslev J, Marks SC Jr, Pockwinse S, Kassem M, Brixen K, Steiniche T, et al. Ultrastructural investigations of bone resorptive cells in two types of autosomal dominant osteopetrosis. Bone 1993; 14(6):865-9.
215. Babij P, Zhao W, Small C, Kharode Y, Yaworsky PJ, Bouxsein ML, et al. High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 2003; 18(6):960-74.
216. Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002; 70(1):11-9.
217. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002; 346(20):1513-21.
218. Johnson ML, Harnish K, Nusse R, Van Hul W. LRP5 and Wnt signaling: a union made for bone. J Bone Miner Res 2004; 19(11):1749-57.